Definition
US FDA substance register · UNII 1O6WQ6T7G3 · registered name Tafluprost · single chemical substance
Tafluprost is a prostaglandin Falpha that is prostaglandin F2alpha in which the carboxylic acid function has been converted to the corresponding isopropyl ester and the 3-hydroxy-1-octenyl side-chain is substituted by 3,3-difluoro-4-phenoxybut-1-enyl. Used for treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It has a role as a prostaglandin receptor agonist. It is an isopropyl ester, a prostaglandins Falpha and an organofluorine compound. It is functionally related to a prostaglandin F2alpha.
Source: PubChem
Cosmetic roles
Safety & regulatory references
- Banned
- Canada
Source: MFDS (Korea) cosmetic regulatory information
Health Canada Cosmetic Ingredient Hotlist · prohibited in cosmetics
Other restriction: ban substances that deplete the ozone layer
Source: EU CosIng ingredient list
More data — names, identifiers, properties, test records, literature
Names & identifiers
- CAS No.chemical registry number
- 209860-87-7
- DTXSIDUS EPA chemical ID
- DTXSID401021504
- DTXCIDUS EPA compound ID
- DTXCID601506522
- IUPAC
- Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl}hept-5-enoate
- Molecular formula
- C25H34F2O5
- Molecular weight
- 452.539 g/mol
Measured properties
- Appearance
- Liquid
- Boiling point
- 100°C
- Melting point
- 87.5 °C
- Solubility
- Insoluble · 5.28e-03 g/L
- Dissociation constant
- 5.5-6.7
Values measured on the substance itself, not a specification for a commercial raw material.
Source: PubChem
What products actually use it for
What the 1 products reported to the US EPA with this ingredient use it for. Products outside cosmetics are included, so the top few rows are its main uses.
- Softener and conditioner1
Source: US EPA CompTox dashboard
Related literature
- Effects of Tafluprost on Ocular Blood Flow · 2022
- Effects of 0.0015% preservative-free tafluprost on the equine eye. · 2021
- Efficacy of preserved Tafluprost 0.0015% in lowering intraocular pressure · 2023
- Assessment of the optic nerve head, peripapillary, and macular microcirculation in the newly diagnosed patients with primary open-angle glaucoma treated with topical tafluprost and tafluprost/timolol fixed combination · 2019
- Efficacy and Safety of Switching from Tafluprost to a Tafluprost/Timolol Fixed Combination in Patients With Primary Open-Angle Glaucoma · 2018
Linked databases 14
- ChEBI
- ChEMBL
- EU CosIng ingredient list 2
- Health Canada Cosmetic Ingredient Hotlist
- MFDS (Korea) cosmetic regulatory information 2 3
- PubChem 2
- Tlooto literature search 2 3 4 5
- UniChem cross-reference IDs
- US EPA CompTox dashboard 2
- US EPA DSSTox chemical database
- US FDA substance registration (GSRS)
- US FDA Unique Ingredient Identifier (UNII)
- Wikidata
- Wikipedia · Korean · English · Japanese · Chinese